Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the women's interagency HIV study

被引：21

作者：

Ahdieh-Grant, L

Tarwater, PM

Schneider, ME

Anastos, K

Cohen, M

Khalsa, A

Minkoff, H

Young, M

Greenblatt, RM

机构：

[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA

[2] Univ Texas, Sch Publ Hlth, Houston, TX USA

[3] Montefiore Med Ctr, Bronx, NY 10467 USA

[4] Cook Cty Hosp, Chicago, IL 60612 USA

[5] Univ So Calif, Sch Med, Los Angeles, CA USA

[6] Maimonides Hosp, Brooklyn, NY 11219 USA

[7] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[8] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[9] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2005年 / 38卷 / 04期

关键词：

antiretroviral therapy; cohort studies; discontinuation; HIV/AIDS;

D O I：

10.1097/01.qai.0000138160.91568.19

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We characterized factors and temporal trends associated with discontinuation of highly active antiretroviral therapy (HAART) among 936 HIV-infected women enrolled in the Women's Interagency HIV Study. A multivariate analysis of post-HAART initiation exposures found that high HIV RNA levels (relative hazard [RH] = 1.36, P < 0.001) and high depressive symptom scores (RH = 1.53, P = 0.012) were associated with HAART discontinuation. The adjusted hazard of discontinuation was higher in the 2 most recent calendar periods compared with the first (RH = 1.61, P = 0.026; RH = 1.56, P = 0.074, respectively). The increasing risk of HAART discontinuation in recent calendar periods and changes in the clinical factors associated with discontinuation reflect ongoing and dynamic shifts in the approach to HAART utilization.

引用

页码：500 / 503

页数：4

共 15 条

[1] The Women's Interagency HIV Study [J].

Barkan, SE ;

Melnick, SL ;

Preston-Martin, S ;

Weber, K ;

Kalish, LA ;

Miotti, P ;

Young, M ;

Greenblatt, R ;

Sacks, H ;

Feldman, J .

EPIDEMIOLOGY, 1998, 9 (02) :117-125

[2] DERIVATION AND PROPERTIES OF A BRIEF HEALTH-STATUS ASSESSMENT INSTRUMENT FOR USE IN HIV DISEASE [J].

BOZZETTE, SA ;

HAYS, RD ;

BERRY, SH ;

KANOUSE, DE ;

WU, AW .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 8 (03) :253-265

[3] Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].

Carpenter, CCJ ;

Cooper, DA ;

Fischl, MA ;

Gatell, JM ;

Gazzard, BG ;

Hammer, SM ;

Hirsch, MS ;

Jacobsen, DM ;

Katzenstein, DA ;

Montaner, JSG ;

Richman, DD ;

Saag, MS ;

Schechter, M ;

Schooley, RT ;

Vella, S ;

Yeni, PG ;

Volberding, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390

[4] Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].

Detels, R ;

Muñoz, A ;

McFarlane, G ;

Kingsley, LA ;

Margolick, JB ;

Giorgi, J ;

Scharager, LD ;

Phair, JP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503

[5]

*DHHS HENR J KAIS, 2001, GUID TREATM HIV INF

[6] Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens [J].

Dorrucci, M ;

Pezzotti, P ;

Grisorio, B ;

Minardi, C ;

Muro, MS ;

Vullo, V ;

Monforte, AD .

AIDS, 2001, 15 (13) :1733-1736

[7] Effectiveness of highly active antiretroviral therapy among HIV-1 infected women [J].

Gange, SJ ;

Barrón, Y ;

Greenblatt, RM ;

Anastos, K ;

Minkoff, H ;

Young, M ;

Kovacs, A ;

Cohen, M ;

Meyer, WA .

JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2002, 56 (02) :153-159

[8] Discontinuation of potent antiretroviral therapy:: predictive value of and impact on CD4 cell counts and HIV RNA levels [J].

Grant, LA ;

Silverberg, MJ ;

Palacio, H ;

Minkoff, H ;

Anastos, K ;

Young, MA ;

Nowicki, M ;

Kovacs, A ;

Cohen, M ;

Muñoz, A .

AIDS, 2001, 15 (16) :2101-2108

[9] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].

Hammer, SM ;

Squires, KE ;

Hughes, MD ;

Grimes, JM ;

Demeter, LM ;

Currier, JS ;

Eron, JJ ;

Feinberg, JE ;

Balfour, HH ;

Dayton, LR ;

Chodakewitz, JA ;

Fischl, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733

[10]

Kleeberger CA, 2001, J ACQ IMMUN DEF SYND, V26, P82, DOI 10.1097/00126334-200101010-00012

← 1 2 →